Basic Information
ID DDInter1093
Drug Type small molecule
Molecular Formula C11H14ClN
Molecular Weight 195.690
CAS Number 616202-92-7
Description Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.[L44042,L44047]
ATC Classification A08AA11
IUPAC Name (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
InChI XTTZERNUQAFMOF-QMMMGPOBSA-N
Canonical SMILES C[C@H]1CNCCC2=CC=C(Cl)C=C12
Useful Links DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC
Interactions with Lorcaserin
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note